Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 84 of 84 matching drugs for MAP2K2 — including drugs targeting any of its 17 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K2 Direct 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K2 Direct 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K2 Direct 2
cft1946, trametinib, cetuximab MAP2K2 Direct 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K2 Direct 2
selumetinib, medi4736, tremelimumab MAP2K2 Direct 2
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib MAP2K2 Direct 1
binimetinib MAP2K2 Direct yes 1
binimetinib, hydroxychloroquine MAP2K2 Direct 1
bosutinib MAP2K2 Direct 1
dabrafenib, trametinib MAP2K2 Direct 1
dabrafenib, trametinib, carboplatin, vincristine MAP2K2 Direct 1
erlotinib hydrochloride, selumetinib, laboratory biomarker analysis MAP2K2 Direct 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim MAP2K2 Direct 1
gsk2256098, trametinib MAP2K2 Direct 1
selumetinib MAP2K2 Direct yes 1
trametinib, erlotinib MAP2K2 Direct 1
trametinib, ruxolitinib MAP2K2 Direct 1
trametinib, ruxolitinib, retifanlimab MAP2K2 Direct 1
trametinib, vinblastine MAP2K2 Direct 1
cobimetinib MAP2K2 Direct yes 0
cobimetinib fumarate MAP2K2 Direct yes 0
selumetinib sulfate MAP2K2 Direct yes 0
trametinib MAP2K2 Direct yes 0
trametinib dimethyl sulfoxide MAP2K2 Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib AKT2 SSL via AKT2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSK SSL via CSK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MST1R SSL via MST1R 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CB SSL via PIK3CB 3
crizotinib MST1R SSL via MST1R 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment CSK SSL via CSK 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
mirdametinib, bgb-3245 MAP2K1 SSL via MAP2K1 2
nivolumab, ipilimumab, cobimetinib MAP2K1 SSL via MAP2K1 2
selumetinib, medi4736, tremelimumab MAP2K1 SSL via MAP2K1 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) MAP2K1 SSL via MAP2K1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CSK SSL via CSK 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib MAP2K1 SSL via MAP2K1 1
bevacizumab, dasatinib, placebo CSK SSL via CSK 1
binimetinib MAP2K1 SSL via MAP2K1 yes 1
binimetinib, hydroxychloroquine MAP2K1 SSL via MAP2K1 1
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging PIK3CB SSL via PIK3CB 1
biopsy, biospecimen collection, copanlisib, radiologic examination PIK3CB SSL via PIK3CB 1
biopsy, biospecimen collection, crizotinib, radiologic examination MST1R SSL via MST1R 1
biopsy, calaspargase pegol-mknl, cobimetinib MAP2K1 SSL via MAP2K1 1
bosutinib MAP2K1 SSL via MAP2K1 1
capivasertib AKT2 SSL via AKT2 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
cobimetinib, hydroxychloroquine, atezolizumab MAP2K1 SSL via MAP2K1 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab MAP2K1 SSL via MAP2K1 1
dabrafenib, trametinib MAP2K1 SSL via MAP2K1 1
dabrafenib, trametinib, carboplatin, vincristine MAP2K1 SSL via MAP2K1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride CSK SSL via CSK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method CSK SSL via CSK 1
dasatinib, laboratory biomarker analysis, physiologic testing CSK SSL via CSK 1
dasatinib, mfolfox6 CSK SSL via CSK 1
dasatinib, pharmacological study CSK SSL via CSK 1
dasatinib, temozolomide, placebo, radiation therapy CSK SSL via CSK 1
disulfiram, copper, alkylating agents GPI SSL via GPI 1
erlotinib hydrochloride, selumetinib, laboratory biomarker analysis MAP2K1 SSL via MAP2K1 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim MAP2K1 SSL via MAP2K1 1
gsk2256098, trametinib MAP2K1 SSL via MAP2K1 1
mirdametinib MAP2K1 SSL via MAP2K1 1
nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, fluorouracil, atezolizumab, cobimetinib, pegph20, bl-8040, selicrelumab, bevacizumab, ro6874281, ab928, tiragolumab, tocilizumab MAP2K1 SSL via MAP2K1 1
pimasertib, gemcitabine, placebo MAP2K1 SSL via MAP2K1 1
rmc-4630, cobimetinib, drug: osimertinib MAP2K1 SSL via MAP2K1 1
selumetinib MAP2K1 SSL via MAP2K1 yes 1
tovorafenib, pimasertib MAP2K1 SSL via MAP2K1 1
trametinib, erlotinib MAP2K1 SSL via MAP2K1 1
trametinib, ruxolitinib MAP2K1 SSL via MAP2K1 1
trametinib, ruxolitinib, retifanlimab MAP2K1 SSL via MAP2K1 1
trametinib, vinblastine MAP2K1 SSL via MAP2K1 1
cobimetinib MAP2K1 SSL via MAP2K1 yes 0
cobimetinib fumarate MAP2K1 SSL via MAP2K1 yes 0
selumetinib sulfate MAP2K1 SSL via MAP2K1 yes 0
trametinib MAP2K1 SSL via MAP2K1 yes 0
trametinib dimethyl sulfoxide MAP2K1 SSL via MAP2K1 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.